US-based healthcare company Johnson & Johnson’s Cilag pharmaceutical division has joined BaseLaunch Phase II, the Basel area-based biotech venture accelerator and incubator in Switzerland run and financed by Basel Area Business & Innovation, the region’s investment and innovation promotion agency.
Roche committed to the second phase of BaseLaunch in May while Pureos became its first venture capital partner in June. Other partners for BaseLaunch Phase II include Roivant Sciences, Bridge Biotherapeutics and CSL Behring.
Nerida Scott, head of Johnson & Johnson Innovation in Europe, said: ” We have been collaborating with BaseLaunch since launch in supporting the growth and development of early-stage biotech ventures and recognize the contribution the team has made towards achieving their goals.”
BaseLaunch helps build companies from inception through to series A funding and in the past two years supported nine early therapeutic ventures which have raised more than $100m.
